AbCellera Biologics Inc. (ABCL)
$3.03
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Key data on ABCL
Market cap
$892836562
EPS
-0.57
P/E ratio
--
Price to sales
77.5
Dividend yield
--
Beta
0.806924
Price on ABCL
Previous close
$3.04
Today's open
$3.02
Day's range
$2.97 - $3.11
52 week range
$1.89 - $6.52
Profile about ABCL
CEO
Carl Hansen
Employees
586
Headquarters
Vancouver, BC
Exchange
Nasdaq Global Select
Shares outstanding
294665532
Issue type
Common Stock
Popular stocks like ABCL
ABCL industries and sectors
Healthcare
Biotechnology & Life Sciences
News on ABCL
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Seeking Alpha • 3 hours ago
AbCellera Reports Full Year 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.
Business Wire • 6 hours ago
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.
Business Wire • Feb 11, 2026
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.
Business Wire • Jan 22, 2026
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Seeking Alpha • Jan 15, 2026
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.
Business Wire • Jan 12, 2026
AbCellera and Bruker Reach Global Settlement of Patent Litigation
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.
Business Wire • Dec 18, 2025
AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Seeking Alpha • Dec 8, 2025
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Business Wire • Dec 8, 2025
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript
AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Analyst Great.
Seeking Alpha • Nov 22, 2025
¹ Disclosures
Invest in AbCellera Biologics Inc.
Open an M1 investment account to buy and sell AbCellera Biologics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.